图式治疗与常规治疗用于门诊难治性抑郁患者:平行组随机临床试验研究方案(DEPRE-ST)
本研究为随机、多中心、平行组、优效性临床试验,计划纳入129例丹麦二级公立精神卫生机构的难治性抑郁门诊患者,按1:1随机接受30次个体图式治疗或常规治疗。主要结局为随机化后12个月时汉密尔顿抑郁量表6项观察者评分较基线的变化,同时评估生活质量、功能损害、心理幸福感、治疗负性效应及成本效果。
要点
- 约三分之一的抑郁患者属于难治性抑郁,其心理治疗效应目前尚不确定。
- 试验比较30次个体图式治疗与常规治疗(主要为团体短期认知行为或心理动力治疗)。
- 主要结局为随机化后12个月时汉密尔顿抑郁量表6项评分较基线的变化。
核心结论
- 该试验将提供图式治疗对比常规治疗用于门诊难治性抑郁的获益、危害及成本效果证据。
- 结果可能改善这一规模大且研究不足的患者群体的治疗。
研究设计与样本
- 随机、多中心、平行组、优效性临床试验,在丹麦二级公立精神卫生机构开展。
- 计划纳入129例难治性抑郁门诊患者,按1:1随机分配至30次个体图式治疗组或常规治疗组。
- 常规治疗在此背景下主要为团体短期认知行为治疗或心理动力治疗。
- 主要结局为随机化后12个月时,观察者评定的汉密尔顿抑郁量表6项评分较基线的变化。
- 次要结局包括欧洲五维五水平量表评估的健康相关生活质量、工作与社会适应量表评估的功能损害、WHO-5幸福感指数评估的心理幸福感、负性效应问卷评估的治疗负性效应。
局限性
- 难治性抑郁研究不足,心理治疗效应目前不确定。
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: About one third of patients with depression are in a condition that can be termed as "difficult-to-treat". Some evidence suggests that difficult-to-treat depression is associated with a higher frequency of childhood trauma and comorbid personality disorders or accentuated features. However, the condition is understudied, and the effects of psychotherapy for difficult-to-treat depression are currently uncertain. The aim of this trial is to investigate the beneficial and harmful effects of 30 sessions of individual schema therapy versus treatment as usual for difficult-to-treat depression in the Danish secondary, public mental health sector. METHODS: In this randomized, multi-centre, parallel-group, superiority clinical trial, 129 outpatients with difficult-to-treat depression will be randomized (1:1) to 30 sessions of individual schema therapy or treatment as usual; in this context mainly group-based, short-term cognitive behaviour or psychodynamic therapy. The primary outcome is the change from baseline in depressive symptoms 12 months after randomization, measured on the observer-rated 6-item Hamilton Rating Scale for Depression. The secondary outcomes are health-related quality of life assessed with the European Quality of Life 5 Dimensions 5 Level Version, functional impairment assessed with the Work and Social Adjustment Scale, psychological wellbeing assessed with the WHO-5 Well-being Index, and negative effects of treatment assessed with the Negative Effects Questionnaire. Exploratory outcomes are improvement on patient self-defined outcomes, personal recovery, anxiety symptoms, anger reactions, metacognitive beliefs about anger, and perseverative negative thinking. Outcomes will be assessed at 6, 12, and 24 months after randomization; the 12-month time-point being the primary time-point of interest. Outcome assessors performing the depression-rating, data managers, statisticians, the data safety and monitoring committee, and conclusion makers for the outcome article will be blinded to treatment allocation and results. To assess cost-effectiveness of the intervention, a health economic analysis will be performed. DISCUSSION: This trial will provide evidence on the beneficial and harmful effects, as well as the cost-effectiveness of schema therapy versus treatment as usual for outpatients with difficult-to-treat depression. The results can potentially improve treatment for a large and understudied patient group. TRIAL REGISTRATION: ClinicalTrials.gov NCT05833087. Registered on 15th April 2023 (approved without prompts for revision on 27th April 2023).
引用
- Arendt ITP, Gondan M, Juul S, et al. Schema therapy versus treatment as usual for outpatients with difficult-to-treat depression: study protocol for a parallel group randomized clinical trial (DEPRE-ST). Trials. 2024. PMID: 38627837. doi:10.1186/s13063-024-08079-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。